"Kaijie" second-generation high-risk human papillomavirus deoxyribonucleic acid qualitative amplification test - Taiwan Registration 5f1a4cc85d34a4bee602fc31a184bcf5
Access comprehensive regulatory information for "Kaijie" second-generation high-risk human papillomavirus deoxyribonucleic acid qualitative amplification test in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 3 medical device is registered under number 5f1a4cc85d34a4bee602fc31a184bcf5 and manufactured by QIAGEN. The authorized representative in Taiwan is QIAGEN TAIWAN COMPANY LIMITED.
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Device Details
Product Details
The hc2 High-Risk HPV DNA Assay Kit with Hybrid Capture 2 (hc2) technology is a nucleic acid hybridization assay that uses microplate chemiluminescence for signal amplification to qualitatively detect 13 high-risk human neoviruses (HPV16/18/31/33/35/35/39/45/51/52/56/58/59/68) DNA in cervical samples.
C Immunology and microbiology
C.0004 Human papillomavirus serum reagent
import
Dates and Status
Dec 27, 2012
Dec 27, 2027